by telrheum | Sep 28, 2024 | Biologic Therapy, Psoriasis, Psoriatic Arthritis
The article reports on the findings from a Phase 2 clinical trial that investigated the effectiveness of Deucravacitinib, a selective Tyrosine Kinase 2 (TYK2) inhibitor, in reducing pain in patients with active Psoriatic Arthritis (PsA). PsA is a chronic inflammatory...
by telrheum | Sep 22, 2024 | Psoriasis, Pericarditis, Pleuritis, Psoriatic Arthritis, Rheumatoid Arthritis, Serositis
This study focused on comparing the frequency of serositis, which refers to inflammation of the lining around the heart (pericarditis) and lungs (pleuritis), between patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA). These conditions are types of...
by telrheum | Sep 22, 2024 | Psoriasis, Acute Phase Reactants, C-reactive Protein, Psoriatic Arthritis
The study titled “Higher Levels of High-sensitivity CRP Are Associated with Future Risk of Developing Psoriatic Arthritis Among Patients with Psoriasis” investigates whether high levels of high-sensitivity C-Reactive Protein (hs-CRP), a marker of inflammation in the...
by telrheum | Mar 31, 2024 | Psoriasis, Psoriatic Arthritis, Spondyloarthritis
Hemay005 is an experimental drug being tested for its ability to treat chronic inflammatory diseases like psoriasis by inhibiting a specific enzyme, PDE4, which plays a key role in the inflammation process. The drug aims to reduce the activity of T lymphocytes and...
